Leishmania Antibody (IgG)
Use
Detection of Leishmania IgG provides strong support for the diagnosis of visceral leishmaniasis. Some (but not all) patients with cutaneous leishmaniasis also have detectable serum levels of Leishmania IgG. Sera from patients with Trypanosoma cruzi infection (Chagas’ disease) show significant cross-reactivity in the Leishmania IgG assay; results should be used in conjunction with other clinical findings.([jdos.nicholsinstitute.com](https://jdos.nicholsinstitute.com/dos/AAMC/test/418037?utm_source=openai))
Special Instructions
Not provided.
Limitations
This assay’s use in diagnosing cutaneous leishmaniasis is limited, since a detectable antibody response is often absent in that form of the disease. Cross-reactivity with Chagas’ disease (Trypanosoma cruzi infection) may occur; results should be interpreted in the appropriate clinical context.([jdos.nicholsinstitute.com](https://jdos.nicholsinstitute.com/dos/AAMC/test/418037?utm_source=openai))
Methodology
Immunoassay (ELISA)
Biomarkers
Result Turnaround Time
1-8 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.2 mL
Minimum Volume
0.1 mL
Container
Red Top (no additive)
Causes for Rejection
Gross hemolysis • Gross lipemia
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 7 days |
| Refrigerated | 14 days |
| Frozen | 30 days |
Other tests from different labs that may be relevant